Addiction as a brain disease revised: why it still matters, and the need for consilience
NPP BrainPodShow Notes
Nearly 25 years ago, a paper was published about addiction that transformed the field. The director of the US National Institute on Drug Abuse at the time called addiction a “brain disease,” and he wrote a paper articulating this position and the agenda that it implied. It led to a focus on researching the brain to understand the mechanisms behind addiction, which could lead to novel treatments. And it meant that the country began to treat addiction as a disease, thus treating it within the medical system and removing the victim-blaming stigma. Over the years, there has been a pushback against the view of addiction as a brain disease, even within the scientific community. In part, this occurred because research in neuroscience didn’t lead to effective treatments as quickly as the field hoped or promised. And in part, says Markus Heilig, it’s because other researchers felt that funding into the neuroscience of addition meant that other relevant mechanisms, such as social and psychological factors, were perhaps being somewhat neglected. Dr. Heilig and his colleagues recently published a review addressing these and other concerns. Listen in to learn more! Hosted on Acast. See acast.com/privacy for more information.
More from NPP BrainPod
Problematic alcohol use frequently occurs in conjunction with anxiety disorders. Between 20 to 40 percent of individuals with anxiety disorders are also diagnosed with alcohol use disorder. Anxiety can lead people to use alcohol to self-medicate, and disordered alcohol use can cause increased anxiety for people when they go through withdrawal.
Insomnia and depression are two serious and debilitating conditions. Insomnia on its own is linked to an increase in suicide risk, and insomnia can also exacerbate the severity of depression.
There are a number of theories that have been studied to try to explain addiction and drug use escalation, and thus to also create animal models of that behavior that can then serve to help develop treatments. One theory for escalation is that people feel worse and worse over time and so they take the drug to feel better. Another is that they just don’t get as much of a reaction to the drug and so need more and more of it to get the euphoria. And then there’s something called incentive salience, which is a craving for the drug.
Oxytocin has become known for having anti-anxiety and affiliative behavioral effects. That’s why clinicians and researchers are excited about using oxytocin as a potential therapeutic.
Cannabis, which is increasingly legally available, both for therapeutic and recreational use, is now one of the most commonly used drugs worldwide. Of people who have ever used cannabis, studies vary, but they estimate that about 10-25 percent of people who use cannabis go on to develop cannabis use disorder.